Debevoise Advises Lauro 57 in Its Completed Sale of Euticals to Albany Molecular Research

11 July 2016

Debevoise & Plimpton LLP has advised Lauro Cinquantasette S.p.A. (Lauro 57) in its sale of Prime European Therapeuticals S.p.A. (Euticals) to Albany Molecular Research, Inc. (AMRI). Euticals is a privately held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs).

AMRI financed the €315 million transaction through the issuance of approximately 7.1 million shares of AMRI common stock (valued at signing), seller notes totaling €55 million and the remainder in cash.

The Debevoise team was led by partner Maurizio Levi-Minzi and included partner Peter A. Furci and associates Vincent J. Bianco, Matthew M. Delja and Keny Zurita.